Literature DB >> 29939318

Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms.

Kelly L Warfield1, Katie A Howell1, Hong Vu1, Joan Geisbert2, Gary Wong3, Sergey Shulenin1, Stephanie Sproule4, Frederick W Holtsberg1, Daisy W Leung5, Gaya K Amarasinghe5, Dana L Swenson6, Sina Bavari6, Gary P Kobinger3, Thomas W Geisbert2, M Javad Aman1.   

Abstract

Background: Several vaccine platforms have been successfully evaluated for prevention of Ebola virus (EBOV) disease (EVD) in nonhuman primates and humans. Despite remarkable efficacy by multiple vaccines, the immunological correlates of protection against EVD are incompletely understood.
Methods: We systematically evaluated the antibody response to various EBOV proteins in 79 nonhuman primates vaccinated with various EBOV vaccine platforms. We evaluated the serum immunoglobulin (Ig)G titers against EBOV glycoprotein (GP), the ability of the vaccine-induced antibodies to bind GP at acidic pH or to displace ZMapp, and virus neutralization titers. The correlation of these outcomes with survival from EVD was evaluated by appropriate statistical methods.
Results: Irrespective of the vaccine platform, protection from EVD strongly correlated with anti-GP IgG titers. The GP-directed antibody levels required for protection in animals vaccinated with virus-like particles (VLPs) lacking nucleoprotein (NP) was significantly higher than animals immunized with NP-containing VLPs or adenovirus-expressed GP, platforms that induce strong T-cell responses. Furthermore, protective immune responses correlated with anti-GP antibody binding strength at acidic pH, neutralization of GP-expressing pseudovirions, and the ability to displace ZMapp components from GP. Conclusions: These findings suggest key quantitative and qualitative attributes of antibody response to EVD vaccines as potential correlates of protection.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29939318      PMCID: PMC6249597          DOI: 10.1093/infdis/jiy316

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  49 in total

1.  Toxicity and primary irritation of some chemical compounds following oral administration and skin application.

Authors:  J H DRAIZE; E ALVAREZ; M F WHITESELL
Journal:  Fed Proc       Date:  1946

2.  Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability.

Authors:  Xuelian Zhao; Katie A Howell; Shihua He; Jennifer M Brannan; Anna Z Wec; Edgar Davidson; Hannah L Turner; Chi-I Chiang; Lin Lei; J Maximilian Fels; Hong Vu; Sergey Shulenin; Ashley N Turonis; Ana I Kuehne; Guodong Liu; Mi Ta; Yimeng Wang; Christopher Sundling; Yongli Xiao; Jennifer S Spence; Benjamin J Doranz; Frederick W Holtsberg; Andrew B Ward; Kartik Chandran; John M Dye; Xiangguo Qiu; Yuxing Li; M Javad Aman
Journal:  Cell       Date:  2017-05-18       Impact factor: 41.582

3.  Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies.

Authors:  Surender Khurana; Sandra Fuentes; Elizabeth M Coyle; Supriya Ravichandran; Richard T Davey; John H Beigel
Journal:  Nat Med       Date:  2016-10-31       Impact factor: 53.440

4.  Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner.

Authors:  Asuka Nanbo; Masaki Imai; Shinji Watanabe; Takeshi Noda; Kei Takahashi; Gabriele Neumann; Peter Halfmann; Yoshihiro Kawaoka
Journal:  PLoS Pathog       Date:  2010-09-23       Impact factor: 6.823

5.  Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail.

Authors:  James Pettitt; Larry Zeitlin; Do H Kim; Cara Working; Joshua C Johnson; Ognian Bohorov; Barry Bratcher; Ernie Hiatt; Steven D Hume; Ashley K Johnson; Josh Morton; Michael H Pauly; Kevin J Whaley; Michael F Ingram; Ashley Zovanyi; Megan Heinrich; Ashley Piper; Justine Zelko; Gene G Olinger
Journal:  Sci Transl Med       Date:  2013-08-21       Impact factor: 17.956

6.  Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge.

Authors:  Kelly L Warfield; Dana L Swenson; Gene G Olinger; Warren V Kalina; M Javad Aman; Sina Bavari
Journal:  J Infect Dis       Date:  2007-11-15       Impact factor: 5.226

7.  Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses.

Authors:  Thomas W Geisbert; Kathleen M Daddario-Dicaprio; Joan B Geisbert; Douglas S Reed; Friederike Feldmann; Allen Grolla; Ute Ströher; Elizabeth A Fritz; Lisa E Hensley; Steven M Jones; Heinz Feldmann
Journal:  Vaccine       Date:  2008-10-18       Impact factor: 3.641

8.  Homologous and heterologous protection of nonhuman primates by Ebola and Sudan virus-like particles.

Authors:  Kelly L Warfield; John M Dye; Jay B Wells; Robert C Unfer; Frederick W Holtsberg; Sergey Shulenin; Hong Vu; Dana L Swenson; Sina Bavari; M Javad Aman
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

9.  Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.

Authors:  Xiangguo Qiu; Gary Wong; Jonathan Audet; Alexander Bello; Lisa Fernando; Judie B Alimonti; Hugues Fausther-Bovendo; Haiyan Wei; Jenna Aviles; Ernie Hiatt; Ashley Johnson; Josh Morton; Kelsi Swope; Ognian Bohorov; Natasha Bohorova; Charles Goodman; Do Kim; Michael H Pauly; Jesus Velasco; James Pettitt; Gene G Olinger; Kevin Whaley; Bianli Xu; James E Strong; Larry Zeitlin; Gary P Kobinger
Journal:  Nature       Date:  2014-08-29       Impact factor: 49.962

Review 10.  Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule.

Authors:  Nancy J Sullivan; Julie E Martin; Barney S Graham; Gary J Nabel
Journal:  Nat Rev Microbiol       Date:  2009-05       Impact factor: 60.633

View more
  12 in total

Review 1.  Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates.

Authors:  John J Suschak; Connie S Schmaljohn
Journal:  Hum Vaccin Immunother       Date:  2019-10-07       Impact factor: 3.452

2.  Recombinant subunit vaccines protect guinea pigs from lethal Ebola virus challenge.

Authors:  Axel T Lehrer; Teri-Ann S Wong; Michael M Lieberman; Lisa Johns; Liana Medina; Friederike Feldmann; Heinz Feldmann; Andrea Marzi
Journal:  Vaccine       Date:  2019-07-16       Impact factor: 3.641

Review 3.  A Historical Review of Military Medical Strategies for Fighting Infectious Diseases: From Battlefields to Global Health.

Authors:  Roberto Biselli; Roberto Nisini; Florigio Lista; Alberto Autore; Marco Lastilla; Giuseppe De Lorenzo; Mario Stefano Peragallo; Tommaso Stroffolini; Raffaele D'Amelio
Journal:  Biomedicines       Date:  2022-08-22

4.  Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study.

Authors:  Eleonora Vianello; Patricia Gonzalez-Dias; Suzanne van Veen; Carmen G Engele; Edwin Quinten; Thomas P Monath; Donata Medaglini; Francesco Santoro; Angela Huttner; Sheri Dubey; Michael Eichberg; Francis M Ndungu; Peter G Kremsner; Paulin N Essone; Selidji Todagbe Agnandji; Claire-Anne Siegrist; Helder I Nakaya; Tom H M Ottenhoff; Mariëlle C Haks
Journal:  Lancet Microbe       Date:  2021-12-06

5.  Prominent Neutralizing Antibody Response Targeting the Ebolavirus Glycoprotein Subunit Interface Elicited by Immunization.

Authors:  Yimeng Wang; Katie A Howell; Jennifer Brannan; Krystle N Agans; Hannah L Turner; Ariel S Wirchnianski; Shweta Kailasan; Marnie Fusco; Andrey Galkin; Chi-I Chiang; Xuelian Zhao; Erica Ollmann Saphire; Kartik Chandran; Andrew B Ward; John M Dye; M Javad Aman; Thomas W Geisbert; Yuxing Li
Journal:  J Virol       Date:  2021-02-03       Impact factor: 6.549

6.  Post-exposure immunotherapy for two ebolaviruses and Marburg virus in nonhuman primates.

Authors:  Jennifer M Brannan; Shihua He; Katie A Howell; Laura I Prugar; Wenjun Zhu; Hong Vu; Sergey Shulenin; Shweta Kailasan; Henna Raina; Gary Wong; Md Niaz Rahim; Logan Banadyga; Kevin Tierney; Xuelian Zhao; Yuxing Li; Frederick W Holtsberg; John M Dye; Xiangguo Qiu; M Javad Aman
Journal:  Nat Commun       Date:  2019-01-10       Impact factor: 14.919

7.  Conserved B and T cell epitopes prediction of ebola virus glycoprotein for vaccine development: An immuno-informatics approach.

Authors:  Bilal Ahmad; Usman Ali Ashfaq; Mahmood-Ur Rahman; Muhammad Shareef Masoud; Muhammad Zubair Yousaf
Journal:  Microb Pathog       Date:  2019-05-07       Impact factor: 3.738

8.  Ebola vaccine-induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects.

Authors:  Michelle Meyer; Bronwyn M Gunn; Delphine C Malherbe; Karthik Gangavarapu; Asuka Yoshida; Colette Pietzsch; Natalia A Kuzmina; Erica Ollmann Saphire; Peter L Collins; James E Crowe; James J Zhu; Marc A Suchard; Douglas L Brining; Chad E Mire; Robert W Cross; Joan B Geisbert; Siba K Samal; Kristian G Andersen; Galit Alter; Thomas W Geisbert; Alexander Bukreyev
Journal:  Sci Transl Med       Date:  2021-07-14       Impact factor: 17.956

Review 9.  Viral genomics in Ebola virus research.

Authors:  Nicholas Di Paola; Mariano Sanchez-Lockhart; Xiankun Zeng; Jens H Kuhn; Gustavo Palacios
Journal:  Nat Rev Microbiol       Date:  2020-05-04       Impact factor: 78.297

10.  Pseudotyping of VSV with Ebola virus glycoprotein is superior to HIV-1 for the assessment of neutralising antibodies.

Authors:  Kimberley Steeds; Yper Hall; Gillian S Slack; Stephanie Longet; Thomas Strecker; Sarah Katharina Fehling; Edward Wright; Joseph Akoi Bore; Fara Raymond Koundouno; Mandy Kader Konde; Roger Hewson; Julian A Hiscox; Georgios Pollakis; Miles W Carroll
Journal:  Sci Rep       Date:  2020-08-31       Impact factor: 4.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.